# A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors

> **NCT03967093** · PHASE1 · TERMINATED · sponsor: **Bexion Pharmaceuticals, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BXQ-350

## Key facts

- **NCT ID:** NCT03967093
- **Lead sponsor:** Bexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-15
- **Primary completion:** 2020-01-03
- **Final completion:** 2020-01-17
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Bexion will not move forward with the Part 2 expansion portion of the trial in order to focus resources on the further development of BXQ-350 as an earlier treatment measure in the pediatric population.
- **Last updated:** 2021-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03967093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03967093, "A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03967093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*